NDLI: Risk minimization activities of centrally authorized products in the EU: a descriptive study.

Please wait, while we are loading the content...

Year: 2017 Volume: 40

Year: 2016 Volume: 39

Year: 2015 Volume: 38

Year: 2014 Volume: 37

Year: 2013 Volume: 36

Year: 2012 Volume: 35

Year: 2012 Volume: 35 Issue: 12

Year: 2012 Volume: 35 Issue: 11

Year: 2012 Volume: 35 Issue: 10

Year: 2012 Volume: 35 Issue: 9

Year: 2012 Volume: 35 Issue: 8

Year: 2012 Volume: 35 Issue: 7

Year: 2012 Volume: 35 Issue: 6

Year: 2012 Volume: 35 Issue: 5

Year: 2012 Volume: 35 Issue: 4

Deriving dose limits for warnings in electronic prescribing systems: statistical analysis of prescription data at University Hospital Birmingham, UK.

Assessing opioid shopping behaviour: a large cohort study from a medication dispensing database in the US.

Risk minimization activities of centrally authorized products in the EU: a descriptive study.

Embedding 'speaking up' into systems for safe healthcare product development and marketing surveillance.

Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.

Clinical diagnosis: a topic worth revisiting for pharmacovigilance.

Safety of flecainide.

Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection.

Year: 2012 Volume: 35 Issue: 3

Year: 2012 Volume: 35 Issue: 2

Year: 2012 Volume: 35 Issue: 1

Year: 2012 Volume: 35 Issue: Supplementary 1

Year: 2011 Volume: 34

Year: 2010 Volume: 33

Year: 2009 Volume: 32

Year: 2008 Volume: 31

Risk minimization activities of centrally authorized products in the EU: a descriptive study.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Zomerdijk, Inge M. Sayed-Tabatabaei, Fakhredin A. Trifirò, Gianluca Blackburn, Stella C. F. Sturkenboom, Miriam C. J. M. Straus, Sabine M. J. M.
Description	Country affiliation: Netherlands Author Affiliation: Zomerdijk IM ( Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands. i.zomerdijk@erasmusmc.nl)
Abstract	BACKGROUND: : Since the new legislation on risk management, which came into force in November 2005, an EU Risk Management Plan (EU-RMP) is a required part of the authorization dossier of innovative drugs licensed in the EU. The EU-RMP can include additional risk minimization activities (RMAs) to strengthen the benefit-risk balance of a drug. This study describes the additional RMAs of centrally authorized medicinal products authorized between 1 January 1995 and 1 January 2010. METHODS: : The European Public Assessment Reports of all centrally authorized products were analysed to identify characteristics of the product (active substance, authorization date, Anatomical Therapeutic Chemical classification), the additional RMAs and the corresponding safety concerns (classified at Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class level). RESULTS: : Additional RMAs were identified for 58 of the 391 active substances that were authorized as of 1 January 2010. The proportion of active substances with additional RMAs was 5% among those authorized before, and 29% among those approved after the new risk management legislation. Since the new legislation, blood products and antineoplastic and immunomodulating agents most often had additional RMAs. All active substances with additional RMAs required the provision of educational material, most frequently involving healthcare professionals (n = 57) and the patient (n = 31). Thirty-three active substances required additional RMAs on top of the provision of educational material, most frequently including patient monitoring and screening (n = 19). CONCLUSIONS: : The proactive pharmacovigilance approach is evolving and the number of products with additional RMAs is growing since the introduction of the EU-RMP. The provision of educational material is the primary additional risk minimization strategy in the EU. The effect of additional RMA implementation has to be explored.
File Format	HTM / HTML
ISSN	01145916
Issue Number	4
Volume Number	35
e-ISSN	11791942
Journal	Drug Safety
Language	English
Publisher	Springer
Publisher Date	2012-04-01
Publisher Place	New Zealand (Aotearoa)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Toxicology Adverse Drug Reaction Reporting Systems Standards Drug Approval Legislation & Jurisprudence Drug-related Side Effects And Adverse Reactions Legislation, Drug Pharmacovigilance Risk Management Methods European Union Humans Patient Education As Topic Journal Article
Content Type	Text
Resource Type	Article
Subject	Toxicology Pharmacology Pharmacology (medical)

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in